Dupixent MDL Leadership Fight: What Early Organization Means for Patients

Why Leadership Appointments Are in the News

Recent reporting by AboutLawsuits.com describes plaintiffs’ lawyers seeking leadership positions in the federal litigation over Dupixent (dupilumab) and cutaneous T-cell lymphoma (CTCL). These lawsuits name Sanofi and Regeneron and have been consolidated in federal court in New Jersey, according to reports including one from Lieff Cabraser. The proceeding is MDL 3180, which was centralized in June 2026.

If you or a family member was diagnosed with CTCL, mycosis fungoides, or Sézary syndrome after receiving Dupixent for eczema or atopic dermatitis, these headlines may raise questions. This post explains what the leadership process is, what it does not mean, and why the stage the litigation is in matters.

What Centralization Does and Does Not Mean

When the Judicial Panel on Multidistrict Litigation centralizes cases, it sends similar federal lawsuits to one judge so that pretrial matters such as evidence exchange and expert challenges can be handled together. This is a case-management decision.

It is important to be clear about one point:

• Centralization is not a finding that Dupixent caused anyone’s cancer.
• It does not decide whether Sanofi or Regeneron is responsible for anything.
• It does not indicate how any individual claim will resolve.

The Judicial Panel decides only whether grouping the cases is efficient. Every question about the merits remains open.

What Leadership Committees Do

In a multidistrict litigation, the presiding judge usually appoints a small group of plaintiffs’ attorneys to coordinate the work that affects every case. Depending on the order, this group may be called lead counsel, a steering committee, or an executive committee. Its responsibilities commonly include:

• Coordinating discovery, which means requesting company documents and taking depositions
• Retaining and preparing experts on general medical questions
• Negotiating case-management orders that set schedules and filing procedures
• Communicating with the court on behalf of the plaintiff group

The U.S. District Court for the District of New Jersey is where the proceeding sits. Individual plaintiffs still keep their own attorneys, and each claim remains a separate lawsuit. The general process is described on the U.S. Courts website.

The Two Theories Plaintiffs Have Pleaded

The complaints, as reported, rely on two distinct allegations. Both are under examination, and neither has been proven.

1. Causation or acceleration. Plaintiffs allege that Dupixent may cause a cutaneous T-cell lymphoma, or may speed the progression of one. One reported lawsuit alleges that the drug “caused T-cell lymphoma or rapidly progressed cancer.”

2. Masking and delayed diagnosis. Plaintiffs also allege that Dupixent may mask the early skin symptoms of a lymphoma the patient already had. Early mycosis fungoides can resemble eczema. The allegation is that treating what looked like eczema may have hidden the developing lymphoma and delayed an accurate diagnosis.

The second theory matters for one group of people in particular. Someone who was diagnosed before starting Dupixent, or whose lymphoma may have been present before treatment, is not automatically excluded. Whether a particular history fits either theory requires review of the individual medical records.

Why Early-Stage Litigation Calls for Caution

This litigation is at its beginning. Very little has been established through discovery, expert testimony, or court rulings. That means:

• No court has decided whether Dupixent is linked to CTCL.
• No bellwether trials have taken place.
• No one can responsibly predict timing, results, or outcomes.

You may see estimates elsewhere about case values or how large the litigation will become. We do not make those projections, and you should treat them with skepticism. Information on cutaneous lymphomas generally is available from the National Cancer Institute. Drug safety communications are published by the FDA.

Understanding the Diagnoses Involved

Cutaneous T-cell lymphoma is a group of cancers that begin in T-cells and appear in the skin. The forms most often mentioned in these lawsuits are:

• Mycosis fungoides, the most common form, which can appear as scaly patches or plaques
• Sézary syndrome, a less common form that involves the blood as well as the skin

Diagnosis typically requires a skin biopsy, sometimes more than one, along with blood tests. Many patients go through several rounds of evaluation before they receive a confirmed diagnosis. Those records, including dermatology notes, pathology reports, and pharmacy history, are the documents that matter most in evaluating any claim.

What Patients Can Do Now

You do not need to wait for leadership appointments or court rulings to understand your situation. Practical steps include:

• Continue following your oncologist’s and dermatologist’s advice. Do not stop or change any medication without talking to your doctor.
• Write down your timeline, including when you started Dupixent, when your symptoms changed, and when you were diagnosed.
• Keep your records if you already have them. You do not need to collect everything yourself, because an attorney can request records from your providers and pharmacy.
• Be aware of filing deadlines. Each state sets its own time limits, and an MDL does not pause them for people who have not filed.

You can learn more on our Dupixent lymphoma practice page.

Families and Wrongful Death Questions

Some families are dealing with the loss of a loved one who was diagnosed with CTCL after Dupixent treatment. In many states, a surviving spouse, child, or estate representative may be able to pursue a claim. The rules on who may file and when vary by state, so an individual review is the reliable way to find out what applies.

Take the Next Step

The Dupixent litigation is still being organized, and nothing has been decided about the merits of these claims. If you received Dupixent and were later diagnosed with mycosis fungoides, Sézary syndrome, or another cutaneous T-cell lymphoma, a conversation with our team can help you understand where you stand. This also applies if your lymphoma may have been present before treatment and you believe the diagnosis was delayed.

Request a free, confidential case review and our team will look at your history with you. There is no cost to ask, and asking does not commit you to anything.